Skip to Main Content
Our Commitment to Diversity

REPRESENTATIVE EXPERIENCE

Coleman Wombwell

Capital Markets

Served as U.S. counsel for MDxHealth SA (NASDAQ: MDXH), a commercial-stage precision diagnostics company, in its initial public offering of American Depositary Shares on the Nasdaq Capital Market. Piper Sandler and Oppenheimer & Co. Inc. served as lead underwriter in the offering, which raised US$45 million of proceeds for the company
Represented Exact Sciences Corporation (NASD: EXAS), a leading provider of cancer screening and diagnostic tests, in its February 2020 offering of $1.0 billion aggregate principal amount of 0.3750% convertible senior notes due 2028 and concurrent repurchase of a portion of its existing 1.0% convertible senior notes due 2025
Represented Exact Sciences Corporation (NASD: EXAS), a leading provider of cancer screening and diagnostic tests, in its October 2020 registered direct offering of $869.2 million of its common stock
Represented Tyler Technologies (NYSE: TYL), a provider of integrated software and technology services to the public sector, in its March 2021 Rule 144A offering of $600.0 million principal amount of its 0.25% convertible senior notes due 2026
Represented NeoGenomics, Inc. (NASD: NEO), a leading provider of cancer-focused genetics testing services and global oncology contract research services, in ts concurrent public underwritten offerings of $200.0 million of its common stock and $300.0 million principal amount of its 0.25% convertible senior notes due 2028
Represented NextDecade Corporation (NASD: NEXT), a liquefied natural gas (LNG) development company developing a LNG terminal and carbon capture project in the Port of Brownsville, Texas, in its private placements of three series of convertible preferred stock for over $135 million of proceeds
Represented NextDecade Corporation (NASD: NEXT), a liquefied natural gas (LNG) development company developing a LNG terminal and carbon capture project in the Port of Brownsville, Texas, in a $50 million investment by an Abu Dhabi-based sovereign investor through a private placement of common stock
Represented Akoustis Technologies, Inc. (NASD: AKTS), an integrated device manufacturer of high-band RF filters for mobile and other wireless applications, in its $100 million at-the-market equity offering program
Represented Akoustis Technologies, Inc. (NASD: AKTS), an integrated device manufacturer of high-band RF filters for mobile and other wireless applications, in its October 2018 concurrent registered offerings of common stock and 6.5% convertible senior notes due 2023
Represented Cue Biopharma, Inc. (NASD: CUE), an immunotherapy company developing a proprietary class of biologics for the treatment of cancer and autoimmune diseases, in its initial public offering of common stock and listing on the Nasdaq Capital Market
Represented ENDRA Life Sciences Inc. (NASD: NDRA), a developer of thermo-acoustic technology for ultrasound systems, in its initial public offering of units consisting of common stock and warrants and listing on the Nasdaq Capital Market

Mergers & Acquisitions

Advised NextDecade Corporation (NASD: NEXT), a liquefied natural gas (LNG) development company developing a LNG terminal and carbon capture project in the Port of Brownsville, Texas, in its February 2020 sale of Rio Bravo Pipeline Company, LLC for $25 million
Advised Motion & Flow Control Products, Inc., a distributor of fluid connectors and other industrial products, in its acquisition of a complementary business with locations throughout the Southwestern U.S.
Advised private-equity backed regional retailer of automotive part in acquisition of the assets of a New England car battery retailer
Advised private-equity backed provider of products and services to the automated external difibrillator ("AED") marketplace in its acquisition of an online retailer of AED products and training
Assisted healthcare system based in Northeast Indiana in its affiliation with a community mental health center with several facilities in Fort Wayne and surrounding areas
Return to top of page

Email Disclaimer

We welcome your email, but please understand that if you are not already a client of K&L Gates LLP, we cannot represent you until we confirm that doing so would not create a conflict of interest and is otherwise consistent with the policies of our firm. Accordingly, please do not include any confidential information until we verify that the firm is in a position to represent you and our engagement is confirmed in a letter. Prior to that time, there is no assurance that information you send us will be maintained as confidential. Thank you for your consideration.

Accept Cancel